CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs
NCT ID: NCT02779530
Last Updated: 2016-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2011-10-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
NCT00780325
Effects of Cox-II Inhibitor on Biochemical Markers in Cardiovascular-related Adverse Effects
NCT00944866
Anti-inflammatory Agents and Cholesterol Metabolism
NCT01279395
Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain
NCT00115752
Variability in Response to Non-steroidal Anti-inflammatory Drugs
NCT02502006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diclofenac
Diclofenac
50 mg po, b.i.d for 6 days
Placebo
Placebo
Placebo po, b.i.d. for 6 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diclofenac
50 mg po, b.i.d for 6 days
Placebo
Placebo po, b.i.d. for 6 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eduardo Barbosa Coelho
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eduardo Barbosa Coelho
Associate Professor Nephrology Division - Internal Medicine Dept. Ribeirão Preto Medical School University of São Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unidade de Pesquisa Clínica HCRP-USP
Ribeirão Preto, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1131-8461
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.